Animal models of pulmonary hypertension: Rho kinase inhibition

Progress in Biophysics and Molecular Biology

Volumn 109, Issue 3, 2012, Pages 67-75

  Firth, Amy L ^a   Choi, Il Whan ^b   Park, Won Sun ^c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b Inje University College of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

Pulmonary hypertension; RhoA Rho kinase

Indexed keywords

PROTEIN KINASE INHIBITOR; RHO KINASE;

ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

ANIMALIA; EUKARYOTA;

EID: 84864566286     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2012.05.009     Document Type: Review

References (100)

1. Abe K., Shimokawa H., Morikawa K., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004, 94:385-393.
2. Abe K., Tawara S., Oi K., et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J. Cardiovasc. Pharmacol. 2006, 48:280-285.
3. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study Group. N. Engl. J. Med. 1996, 335:609-616.
4. Adnot S., Raffestin B., Eddahibi S., Braquet P., Chabrier P.E. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J. Clin. Invest. 1991, 87:155-162.
5. Alessi D., MacDougall L.K., Sola M.M., Ikebe M., Cohen P. The control of protein phosphatase-1 by targetting subunits. The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. Eur. J. Biochem. 1992, 210:1023-1035.
6. Bailly K., Ridley A.J., Hall S.M., Haworth S.G. RhoA activation by hypoxia in pulmonary arterial smooth muscle cells is age and site specific. Circ. Res. 2004, 94:1383-1391.
7. Barman S.A. Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 293:L472-L479.
8. Boer C., van der Linden P.J., Scheffer G.J., Westerhof N., de Lange J.J., Sipkema P. RhoA/Rho kinase and nitric oxide modulate the agonist-induced pulmonary artery diameter response time. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H990-H998.
9. Bogaard H.J., Natarajan R., Henderson S.C., et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009, 120:1951-1960.
10. Caldwell R.W., Blatteis C.M. Effect of chronic hypoxia on angiotensin-induced pulmonary vasoconstriction and converting enzyme activity in the rat. Proc. Soc. Exp. Biol. Med. 1983, 172:346-350.
11. Casey D.B., Badejo A.M., Dhaliwal J.S., et al. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H184-H192.
12. Chen X.Y., Dun J.N., Miao Q.F., Zhang Y.J. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009, 83:67-79.
13. Chung H.H., Dai Z.K., Wu B.N., et al. KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation. Vascul. Pharmacol. 2010, 53:239-249.
14. Chung H.H., Dai Z.K., Wu B.N., et al. The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase. Br. J. Pharmacol. 2010, 160:971-986.
15. Ciuclan L., Bonneau O., Hussey M., et al. A novel murine model of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2011.
16. +-channel. Life Sci. 2010, 86:747-755.
17. Dhaliwal J.S., Badejo A.M., Casey D.B., Murthy S.N., Kadowitz P.J. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. J. Pharmacol. Exp. Ther. 2009, 330:334-341.
18. Drummond W.H., Bissonnette J.M. Persistent pulmonary hypertension in the neonate: development of an animal model. Am. J. Obstet. Gynecol. 1978, 131:761-763.
19. Eddahibi S., Raffestin B., Braquet P., Chabrier P.E., Adnot S. Pulmonary vascular reactivity to endothelin-1 in normal and chronically pulmonary hypertensive rats. J. Cardiovasc. Pharmacol. 1991, 17(Suppl. 7):S358-S361.
20. Fagan K.A., Fouty B.W., Tyler R.C., et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J. Clin. Invest. 1999, 103:291-299.
21. Fagan K.A., Oka M., Bauer N.R., et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287:L656-L664.
22. Farkas L., Gauldie J., Voelkel N.F., Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am. J. Respir. Cell Mol. Biol. 2011, 45:1-15.
23. Fu X., Gong M.C., Jia T., Somlyo A.V., Somlyo A.P. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. FEBS Lett. 1998, 440:183-187.
24. Fujita H., Fukumoto Y., Saji K., et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010, 25:144-149.
25. 2+-independent regulation of smooth muscle contraction. J. Muscle Res. Cell Motil. 2002, 23:47-52.
26. Gao Y., Portugal A.D., Negash S., Zhou W., Longo L.D., Usha Raj J. Role of Rho kinases in PKG-mediated relaxation of pulmonary arteries of fetal lambs exposed to chronic high altitude hypoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292:L678-L684.
27. Gao Y., Portugal A.D., Liu J., et al. Preservation of cGMP-induced relaxation of pulmonary veins of fetal lambs exposed to chronic high altitude hypoxia: role of PKG and Rho kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295:L889-L896.
28. Gomez-Arroyo J.G., Farkas L., Alhussaini A.A., et al. The monocrotaline model of pulmonary hypertension in Perspective. Am. J. Physiol. Lung Cell Mol. Physiol. 2011.
29. Hamidi S.A., Prabhakar S., Said S.I. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur. Respir. J. 2008, 31:135-139.
30. Hessel M.H., Steendijk P., den Adel B., Schutte C.I., van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2424-H2430.
31. Hirenallur S.D., Haworth S.T., Leming J.T., et al. Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295:L915-L924.
32. Hoffmann J., Yin J., Kukucka M., et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur. Respir. J. 2011, 37:1400-1410.
33. Homma N., Nagaoka T., Morio Y., et al. Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J. Cardiovasc. Pharmacol. 2007, 50:697-702.
34. Howell K., Preston R.J., McLoughlin P. Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J. Physiol. 2003, 547:133-145.
35. Hyvelin J.M., O'Connor C., McLoughlin P. Effect of changes in pH on wall tension in isolated rat pulmonary artery: role of the RhoA/Rho-kinase pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287:L673-L684.
36. Hyvelin J.M., Howell K., Nichol A., Costello C.M., Preston R.J., McLoughlin P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ. Res. 2005, 97:185-191.
37. Ishikura K., Yamada N., Ito M., et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ. J. 2006, 70:174-178.
38. Ishizaki T., Uehata M., Tamechika I., et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 2000, 57:976-983.
39. Janssen L.J., Lu-Chao H., Netherton S. Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 280:L666-L674.
40. Jiang B.H., Tawara S., Abe K., Takaki A., Fukumoto Y., Shimokawa H. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J. Cardiovasc. Pharmacol. 2007, 49:85-89.
41. Johnson D.E., Georgieff M.K. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am. Rev. Respir. Dis. 1989, 140:1807-1812.
42. Keegan A., Morecroft I., Smillie D., Hicks M.N., MacLean M.R. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ. Res. 2001, 89:1231-1239.
43. Kwapiszewska G., Markart P., Dahal B.K., et al. PAR-2 inhibition Reverses Experimental pulmonary hypertension. Circ. Res. 2012, 110:1179-1191.
44. Larsen K.O., Yndestad A., Sjaastad I., et al. Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 301:L50-L59.
45. Leung T., Manser E., Tan L., Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J. Biol. Chem. 1995, 270:29051-29054.
46. Li F., Xia W., Yuan S., Sun R. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr. Cardiol. 2009, 30:363-366.
47. Liu Y., Suzuki Y.J., Day R.M., Fanburg B.L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res. 2004, 95:579-586.
48. Liu Y., Ren W., Warburton R., Toksoz D., Fanburg B.L. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J. 2009, 23:2299-2306.
49. Liu Y., Zhang B., Dong M.Q., et al. Attenuation of pulmonary arterial smooth muscle cell proliferation following hypoxic pulmonary hypertension by the Na+/H+ exchange inhibitor amiloride. Chin. J. Physiol. 2010, 53:36-44.
50. Long L., MacLean M.R., Jeffery T.K., et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ. Res. 2006, 98:818-827.
51. Machado R.D., Aldred M.A., James V., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 2006, 27:121-132.
52. MacLean M.R., Morecroft I. Increased contractile response to 5-hydroxytryptamine1-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergy. Br. J. Pharmacol. 2001, 134:614-620.
53. MacLean M.R., Herve P., Eddahibi S., Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. 2000, 131:161-168.
54. MacLean M.R., Deuchar G.A., Hicks M.N., et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004, 109:2150-2155.
55. Mair K.M., MacLean M.R., Morecroft I., Dempsie Y., Palmer T.M. Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br. J. Pharmacol. 2008, 155:606-616.
56. McMurtry I.F., Bauer N.R., Fagan K.A., Nagaoka T., Gebb S.A., Oka M. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv. Exp. Med. Biol. 2003, 543:127-137.
57. McNamara P.J., Murthy P., Kantores C., et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294:L205-L213.
58. Morecroft I., Heeley R.P., Prentice H.M., Kirk A., MacLean M.R. 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br. J. Pharmacol. 1999, 128:730-734.
59. Mouchaers K.T., Schalij I., de Boer M.A., et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur. Respir. J. 2010, 36:800-807.
60. Nagaoka T., Morio Y., Casanova N., et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287:L665-L672.
61. Nagaoka T., Fagan K.A., Gebb S.A., et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2005, 171:494-499.
62. Nagaoka T., Gebb S.A., Karoor V., et al. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J. Appl. Physiol. 2006, 100:996-1002.
63. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392:189-193.
64. Noguchi Y., Hislop A.A., Haworth S.G. Influence of hypoxia on endothelin-1 binding sites in neonatal porcine pulmonary vasculature. Am. J. Physiol. 1997, 272:H669-H678.
65. Olson J.W., Hacker A.D., Altiere R.J., Gillespie M.N. Polyamines and the development of monocrotaline-induced pulmonary hypertension. Am. J. Physiol. 1984, 247:H682-H685.
66. Parker T.A., Roe G., Grover T.R., Abman S.H. Rho kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 291:L976-L982.
67. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003, 107:2037-2044.
68. Price L.C., Wort S.J., Perros F., et al. Inflammation in pulmonary arterial hypertension. Chest 2012, 141:210-221.
69. + exchange and growth factors in pulmonary artery smooth muscle cell proliferation. Am. J. Respir. Cell Mol. Biol. 1996, 14:139-145.
70. Rabinovitch M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J. Clin. Invest. 2001, 108:1109-1111.
71. Robertson T.P., Dipp M., Ward J.P., Aaronson P.I., Evans A.M. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br. J. Pharmacol. 2000, 131:5-9.
72. Sakurada S., Okamoto H., Takuwa N., Sugimoto N., Takuwa Y. Rho activation in excitatory agonist-stimulated vascular smooth muscle. Am. J. Physiol. Cell Physiol. 2001, 281:C571-C578.
73. Sauzeau V., Rolli-Derkinderen M., Lehoux S., Loirand G., Pacaud P. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ. Res. 2003, 93:630-637.
74. Schermuly R.T., Ghofrani H.A., Wilkins M.R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 2011, 8:443-455.
75. Schwenke D.O., Pearson J.T., Sonobe T., et al. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension. J. Appl. Physiol. 2011, 110:901-908.
76. Seyler C., Duthil-Straub E., Zitron E., et al. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. Br. J. Pharmacol. 2012, 165:1467-1475.
77. Shimoda L.A., Fallon M., Pisarcik S., Wang J., Semenza G.L. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 291:L941-L949.
78. + exchange in pulmonary artery smooth muscle from spontaneously hypertensive and Wistar-Kyoto rats. Am. J. Physiol. 1995, 269:L673-L680.
79. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009, 54:S43-S54.
80. Snow J.B., Gonzalez Bosc L.V., Kanagy N.L., Walker B.R., Resta T.C. Role for PKCbeta in enhanced endothelin-1-induced pulmonary vasoconstrictor reactivity following intermittent hypoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 301:L745-L754.
81. Stenmark K.R., Fagan K.A., Frid M.G. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 2006, 99:675-691.
82. Steudel W., Scherrer-Crosbie M., Bloch K.D., et al. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J. Clin. Invest. 1998, 101:2468-2477.
83. Tada Y., Majka S., Carr M., et al. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292:L1556-L1563.
84. Tawara S., Fukumoto Y., Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J. Cardiovasc. Pharmacol. 2007, 50:195-200.
85. Uehata M., Ishizaki T., Satoh H., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994.
86. van Suylen R.J., Smits J.F., Daemen M.J. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1998, 157:1423-1428.
87. Wang Z., Jin N., Ganguli S., Swartz D.R., Li L., Rhoades R.A. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am. J. Respir. Cell Mol. Biol. 2001, 25:628-635.
88. Wanstall J.C., O'Donnell S.R. Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur. J. Pharmacol. 1990, 176:159-168.
89. Ward J.P., McMurtry I.F. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr. Opin. Pharmacol. 2009, 9:287-296.
90. West J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv. Exp. Med. Biol. 2010, 661:265-278.
91. West J., Harral J., Lane K., et al. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295:L744-L755.
92. + channel expression in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294:L309-L318.
93. Wojciak-Stothard B., Tsang L.Y., Paleolog E., Hall S.M., Haworth S.G. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 290:L1173-L1182.
94. Wray S., Burdyga T., Noble K. Calcium signalling in smooth muscle. Cell Calcium 2005, 38:397-407.
95. Yasuda T., Tada Y., Tanabe N., Tatsumi K., West J. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 301:L667-L674.
96. Yu Y., Fantozzi I., Remillard C.V., et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13861-13866.
97. Yu L., Quinn D.A., Garg H.G., Hales C.A. Deficiency of the NHE1 gene prevents hypoxia-induced pulmonary hypertension and vascular remodeling. Am. J. Respir. Crit. Care Med. 2008, 177:1276-1284.
98. Yu L., Quinn D.A., Garg H.G., Hales C.A. Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/Rho kinase/p27. Am. J. Respir. Cell Mol. Biol. 2011, 44:524-530.
99. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998, 98:1400-1406.
100. Ziino A.J., Ivanovska J., Belcastro R., et al. Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia. Pediatr. Res. 2010, 67:177-182.